📽️Watch NOW & Summit #HCC Mts🏔---🧗🏽AEs w AA ICIs & combos--- 🧗♂️Practical approaches & nuances---🧭w @MarkYarchoan @marinabaretti @MPishvaian---🆓#CME BonumCE🔗bit.ly/3D2O60S---Supp… by edu grants from Eisai & @Merck---#TumorBoardTuesday twitter.com/i/broadcasts/1…
🪂BEFORE diving in 🪂…
🔗👇open link below (right click🖱️> open in 🆕tab)
✅ Answer #PreTest polls
🔁Retweet & tag colleagues
🔗👇open link below (right click🖱️> open in 🆕tab)
✅ Answer #PreTest polls
🔁Retweet & tag colleagues
https://twitter.com/TumorBoardTues/status/1585634735061053444
3/ #TumorBoardTuesday #HCC #OncTwitter #GITwitter #LiverTwitter
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3D2O60S
📸 Faculty disclosures & important CME info 👇
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3D2O60S
📸 Faculty disclosures & important CME info 👇
4/#TumorBoardTuesday #HCC #OncTwitter
Thanks for joining our 🔥HCC Fireside Chat🔥
⌛️Chat is winding down but keep the♨️going
🗳️answer the #PostTest👇
#CME🔗bit.ly/3s2kDPL
🔴#PostTest Q1️⃣
🗳️Hypertension is a common toxicity associated w/ which class/es of drug?
Thanks for joining our 🔥HCC Fireside Chat🔥
⌛️Chat is winding down but keep the♨️going
🗳️answer the #PostTest👇
#CME🔗bit.ly/3s2kDPL
🔴#PostTest Q1️⃣
🗳️Hypertension is a common toxicity associated w/ which class/es of drug?
5/ #TumorBoardTuesday
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 2️⃣
🗳️ Which is a common characteristic of irAEs?
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 2️⃣
🗳️ Which is a common characteristic of irAEs?
6/ #TumorBoardTuesday
🔴#PostTest Q3️⃣
🗳️Pt w metastatic #HCC was treated w atezo-bev
After 4 cycles they developed grade 2 elevation of liver enzymes & both💊 withheld
Liver function tests done 3d later & liver enzymes cont to 📈
Which is most likely causing toxicity?
🔴#PostTest Q3️⃣
🗳️Pt w metastatic #HCC was treated w atezo-bev
After 4 cycles they developed grade 2 elevation of liver enzymes & both💊 withheld
Liver function tests done 3d later & liver enzymes cont to 📈
Which is most likely causing toxicity?
7/ #TumorBoardTuesday
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 4️⃣
🗳️What was the most common grade 3/4 toxicity associated with the use of bevacizumab and atezolizumab combination therapy in the phase 3 IMbrave150 trial?
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 4️⃣
🗳️What was the most common grade 3/4 toxicity associated with the use of bevacizumab and atezolizumab combination therapy in the phase 3 IMbrave150 trial?
8/ #TumorBoardTuesday
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 5️⃣
🗳️Which of the following pts w/ advanced HCC would you consider most appropriate to receive frontline therapy w/ durva + treme?
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q 5️⃣
🗳️Which of the following pts w/ advanced HCC would you consider most appropriate to receive frontline therapy w/ durva + treme?
9/ #TumorBoardTuesday
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q6⃣
🗳️Pt receiving pembro & lenvatinib presents w new onset Grade 2 diarrhea, 3m after their last dose. Colitis ruled out by endoscopy.
What is the optimal mgmt strategy for this pt?
#CME 🔗bit.ly/3s2kDPL
🔴#PostTest Q6⃣
🗳️Pt receiving pembro & lenvatinib presents w new onset Grade 2 diarrhea, 3m after their last dose. Colitis ruled out by endoscopy.
What is the optimal mgmt strategy for this pt?
10/ #ICYMI #TumorBoardTuesday #MedTweetorial 🧵
🔎 #HCC AA, ICIs, & combos
🏔Latest data
🏔Tox to look out for
🏔Tox impact on choice of therapy
🔎 #HCC AA, ICIs, & combos
🏔Latest data
🏔Tox to look out for
🏔Tox impact on choice of therapy
https://twitter.com/TumorBoardTues/status/1585061191457857537
• • •
Missing some Tweet in this thread? You can try to
force a refresh
